35,017 Shares in Core Laboratories Inc. (NYSE:CLB) Purchased by First Trust Advisors LP

First Trust Advisors LP purchased a new stake in shares of Core Laboratories Inc. (NYSE:CLB - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 35,017 shares of the oil and gas company's stock, valued at approximately $606,000. First Trust Advisors LP owned 0.07% of Core Laboratories as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CLB. Barclays PLC grew its holdings in Core Laboratories by 288.2% in the third quarter. Barclays PLC now owns 83,570 shares of the oil and gas company's stock valued at $1,549,000 after purchasing an additional 62,042 shares during the period. Tidal Investments LLC increased its holdings in Core Laboratories by 1.7% in the 3rd quarter. Tidal Investments LLC now owns 43,862 shares of the oil and gas company's stock worth $813,000 after acquiring an additional 716 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Core Laboratories by 5.8% during the third quarter. JPMorgan Chase & Co. now owns 41,281 shares of the oil and gas company's stock valued at $765,000 after purchasing an additional 2,267 shares in the last quarter. Ridgewood Investments LLC raised its position in shares of Core Laboratories by 4.6% during the 4th quarter. Ridgewood Investments LLC now owns 32,612 shares of the oil and gas company's stock worth $565,000 after purchasing an additional 1,428 shares during the last quarter. Finally, Nisa Investment Advisors LLC lifted its stake in Core Laboratories by 2,688.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,426 shares of the oil and gas company's stock valued at $42,000 after buying an additional 2,339 shares in the last quarter. Hedge funds and other institutional investors own 97.81% of the company's stock.

Core Laboratories Trading Up 0.4%

CLB stock traded up $0.05 during trading on Wednesday, reaching $12.51. 118,356 shares of the stock were exchanged, compared to its average volume of 435,675. The business has a 50 day moving average price of $13.18 and a 200-day moving average price of $16.61. Core Laboratories Inc. has a 1 year low of $10.14 and a 1 year high of $25.13. The company has a current ratio of 2.32, a quick ratio of 1.71 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $586.27 million, a price-to-earnings ratio of 18.92, a P/E/G ratio of 0.99 and a beta of 1.45.

Core Laboratories (NYSE:CLB - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The oil and gas company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.01). Core Laboratories had a return on equity of 16.24% and a net margin of 5.99%. The business had revenue of $123.59 million during the quarter, compared to analysts' expectations of $125.09 million. During the same quarter in the previous year, the company posted $0.19 earnings per share. The company's revenue was down 4.7% on a year-over-year basis. On average, research analysts predict that Core Laboratories Inc. will post 0.96 earnings per share for the current year.

Core Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 27th. Stockholders of record on Monday, May 5th will be issued a $0.01 dividend. The ex-dividend date of this dividend is Monday, May 5th. This represents a $0.04 annualized dividend and a dividend yield of 0.32%. Core Laboratories's dividend payout ratio is currently 6.78%.

Analyst Ratings Changes

Several equities analysts have recently weighed in on CLB shares. StockNews.com downgraded Core Laboratories from a "hold" rating to a "sell" rating in a research report on Friday, April 25th. Citigroup dropped their price objective on shares of Core Laboratories from $16.00 to $13.00 and set a "neutral" rating for the company in a research note on Tuesday. Finally, Stifel Nicolaus decreased their target price on shares of Core Laboratories from $19.00 to $15.00 and set a "hold" rating on the stock in a research note on Tuesday, April 15th. Two research analysts have rated the stock with a sell rating and three have issued a hold rating to the company. According to MarketBeat, Core Laboratories presently has a consensus rating of "Hold" and an average price target of $15.00.

Core Laboratories Company Profile

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.